Utomilumab - Pfizer

Drug Profile

Utomilumab - Pfizer

Alternative Names: 4-1BB agonist monoclonal antibody- Pfizer; PF-05082566; PF-2566; PF-5082566

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer M. D. Anderson Cancer Center; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 13 Dec 2017 Stanford University in collaboration with National Cancer Institute plans a phase Ib trial for Breast Cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA in January 2018 (NCT03364348)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Monotherapy) in France (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Monotherapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top